Osteoblast function in myeloma

Bone

Volumn 48, Issue 1, 2011, Pages 135-140

  Roodman, G David ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Bone disease; Cancer; Multiple myeloma; Osteoblast; Osteoclast

Indexed keywords

ACTIVIN A; ALKALINE PHOSPHATASE; ANABOLIC AGENT; BORTEZOMIB; FRIZZLED PROTEIN; INTERLEUKIN 3; INTERLEUKIN 7; MELPHALAN; OSTEOCALCIN; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN;

BONE DESTRUCTION; BONE DEVELOPMENT; BONE DISEASE; BONE LESION; BONE MARROW; BONE REMODELING; CELL CONTACT; CELL DIFFERENTIATION; CELL FUNCTION; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; MESENCHYMAL STEM CELL; MICROENVIRONMENT; MULTIPLE MYELOMA; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN BLOOD LEVEL; REVIEW; SIGNAL TRANSDUCTION;

ALKALINE PHOSPHATASE; BONE AND BONES; BONE REMODELING; BONE RESORPTION; CELL DIFFERENTIATION; HUMANS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCALCIN; OSTEOGENESIS;

EID: 78650417743     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.06.016     Document Type: Review

References (65)

1. Mariotto A, Gigli A, Capocaccia R, Tavilla A, Clegg L X, Depry M, Scoppa S, Ries LAG, Rowland JH, Tesauro G, Feuer EJ. Complete and limited duration cancer prevalence estimates.. SEER Cancer Statistics Review, pp. 19: National Cancer Institute; 2002. http://seer.cancer.gov/csr/1973_1999.
2. Roodman G.D. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004, 32:290-292.
3. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334:488-493. Myeloma Aredia Study Group.
4. Melton L.J., Kyle R.A., Achenbach S.J., Oberg A.L., Rajkumar S.V. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 2005, 20:487-493.
5. Terpos E., Berenson J., Cook R.J., Lipton A., Coleman R.E. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010, 24:1043-1049.
6. Schulman K.L., Kohles J. Economic burden of metastatic bone disease in the United States. Cancer 2007, 109:2334-2342.
7. Saad F., Lipton A., Cook R., Chen Y.M., Smith M., Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110:1860-1867.
8. Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma 2010, 51:213-220.
9. Podar K., Chauhan D., Anderson K.C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009, 23:10-24.
10. Roodman G.D. Bone building with bortezomib. J Clin Invest 2008, 118:462-464.
11. Kumar S.K., Rajkumar S.V., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
12. Calvani N., Silvestris F., Cafforio P., Dammacco F. Osteoclast-like cell formation by circulating myeloma B lymphocytes: role of RANK-L. Leuk Lymphoma 2004, 45:377-380.
13. Hjorth-Hansen H., Seifert M.F., Borset M., Aarset H., Ostlie A., Sundan A., et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 1999, 14:256-263.
14. Giuliani N., Rizzoli V., Roodman G.D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006, 108:3992-3996.
15. Giuliani N., Colla S., Morandi F., Lazzaretti M., Sala R., Bonomini S., et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005, 106:2472-2483.
16. Hideshima T., Chauhan D., Podar K., Schlossman R.L., Richardson P., Anderson K.C. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001, 28:607-612.
17. Ely S.A., Knowles D.M. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 2002, 160:1293-1299.
18. Westendorf J.J., Kahler R.A., Schroeder T.M. Wnt signaling in osteoblasts and bone diseases. Gene 2004, 341:19-39.
19. Bain G., Muller T., Wang X., Papkoff J. Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem Biophys Res Commun 2003, 301:84-91.
20. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
21. Qiang Y.W., Chen Y., Stephens O., Brown N., Chen B., Epstein J., et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008, 112:196-207.
22. Politou M.C., Heath D.J., Rahemtulla A., Szydlo R., Anagnostopoulos A., Dimopoulos M.A., et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006, 119:1728-1731.
23. Kaiser M., Mieth M., Liebisch P., Oberlander R., Rademacher J., Jakob C., et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008, 80:490-494.
24. Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., Shaughnessy J.D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109:2106-2111.
25. Fulciniti M., Tassone P., Hideshima T., Vallet S., Nanjappa P., Ettenberg S.A., et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114:371-379.
26. Oshima T., Abe M., Asano J., Hara T., Kitazoe K., Sekimoto E., et al. Myeloma cells suppress osteoblast differentiation by secreting a soluble wnt inhibitor, sFRP-2. Blood (ASH Meeting Abstracts) 2004, 104:2356.
27. De Vos J., Couderc G., Tarte K., Jourdan M., Requirand G., Delteil M.C., et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001, 98:771-780.
28. Giuliani N., Morandi F., Tagliaferri S., Lazzaretti M., Donofrio G., Bonomini S., et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007, 67:7665-7674.
29. Ehrlich L.A., Chung H.Y., Ghobrial I., Choi S.J., Morandi F., Colla S., et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005, 106:1407-1414.
30. Lee J.W., Chung H.Y., Ehrlich L.A., Jelinek D.F., Callander N.S., Roodman G.D., et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004, 103:2308-2315.
31. Kawasaki T, Niki Y, Miyamoto T, Horiuchi K, Matsumoto M, Aizawa M, Toyama Y The effect of timing in the administration of hepatocyte growth factor to modulate BMP-2-induced osteoblast differentiation. Biomaterials 2010, 31:1191-1198.
32. Standal T., Abildgaard N., Fagerli U.M., Stordal B., Hjertner O., Borset M., et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007, 109:3024-3030.
33. Nanes M.S. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 2003, 321:1-15.
34. Olfa G., Christophe C., Pierre H., Odile B, Jean-Christophe D. TNFalpha's effects on proliferation and apoptosis in human mesenchymal stem cells are dependent on RUNX2 expression. J Bone Miner Res 2010, 25:1616-1626.
35. Esteve F., Hong C.S., Huston A., Garcia-Palacios V., Anderson J., Patrene K., et al. Suppression of mesenchymal stromal cell (MSC) differentiation in multiple myeloma (MM) is restricted to the osteoblast lineage. Blood:Abstract 2008.
36. D'Souza, S, Del Prete D, Sammut B, Esteve F, Yu S, Xiao G, et al. Multiple myeloma cell induction of Gfi-1 in stromal cells suppresses runx2 expression and osteoblast differentiation. University of pittsburgh, presented at IX International Meeting on cancer induced Bone Disease, Arlington VA, October 28-31, 2009.
37. D'Souza S., Prete D.D., Esteve F., Sammut B., Yu S., Xiao G., et al. Multiple myeloma cell induction of Gfi-1 in stromal cells suppresses osteoblast differentiation in patients with myeloma. Blood 2009, 114:742.
38. Vallet S., Mukherjee S., Vaghela N., Hideshima T., Pozzi S., Santo L., et al. Effects of RAP-011, a soluble activin receptor, on multiple myeloma (MM) via targeting the microenvironment. AACR Meeting:Abstract #1521 2008.
39. Vallet S., Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A 2010, 107:5124-5129.
40. Chantry A., Heath D., Coulton L., Gallagher O., Evans H., Seehra J., et al. A soluble activin type II receptor prevents myeloma bone disease. Haematologica 2007, 92(suppl.2). Abstract #PO-319.
41. Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE, Ucran J, et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010, 46:1082-1088.
42. Abdulkadyrov K.M., Salogub G.N., Khuazheva N.K., Woolf R., Haltom E., N.G.B., et al. ACE-011, a soluble activin receptor type Iia IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: preliminary analysis 2009, American Society of Hematology, New Orleans, LA, Abstract #749.
43. Grisham M.B., Palombella V.J., Elliott P.J., Conner E.M., Brand S., Wong H.L., et al. Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome. Methods Enzymol 1999, 300:345-363.
44. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4:349-360.
45. Landowski T.H., Megli C.J., Nullmeyer K.D., Lynch R.M., Dorr R.T. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005, 65:3828-3836.
46. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002, 3:221-227.
47. Hideshima T., Nakamura N., Chauhan D., Anderson K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001, 20:5991-6000.
48. Hideshima T., Chauhan D., Hayashi T., Akiyama M., Mitsiades N., Mitsiades C., et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003, 22:8386-8393.
49. Rajkumar S.V., Kyle R.A. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005, 80:1371-1382.
50. von Metzler I., Krebbel H., Hecht M., Manz R.A., Fleissner C., Mieth M., et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007, 21:2025-2034.
51. Terpos E., Heath D.J., Rahemtulla A., Zervas K., Chantry A., Anagnostopoulos A., et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006, 135:688-692.
52. Terpos E., Sezer O., Croucher P., Dimopoulos M.A. Myeloma bone disease and proteasome inhibition therapies. Blood 2007, 110:1098-1104.
53. Pennisi A., Li X., Ling W., Khan S., Zangari M., Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009, 84:6-14.
54. McConkey D.J. Bortezomib paradigm shift in myeloma. Blood 2009, 114:931-932.
55. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277:16639-16647.
56. Hideshima T., Chauhan D., Ishitsuka K., Yasui H., Raje N., Kumar S., et al. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene 2005, 24:3121-3129.
57. Bennett E.J., Shaler T.A., Woodman B., Ryu K.Y., Zaitseva T.S., Becker C.H., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448:704-708.
58. Qiang Y.W., Hu B., Chen Y., Zhong Y., Shi B., Barlogie B., et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 2009, 113:4319-4330.
59. Zangari M., Esseltine D., Lee C.K., Barlogie B., Elice F., Burns M.J., et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005, 131:71-73.
60. Heider U., Kaiser M., Muller C., Jakob C., Zavrski I., Schulz C.O., et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006, 77:233-238.
61. Giuliani N., Morandi F., Tagliaferri S., Lazzaretti M., Bonomini S., Crugnola M., et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007, 110:334-338.
62. Edwards C.M. Wnt signaling: bone's defense against myeloma. Blood 2008, 112:216-217.
63. Garrett I.R., Chen D., Gutierrez G., Zhao M., Escobedo A., Rossini G., et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003, 111:1771-1782.
64. Oyajobi B.O., Garrett I.R., Gupta A., Flores A., Esparza J., Munoz S., et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 2007, 139:434-438.
65. Ozaki S., Tanaka O., Fujii S., Shigekiyo Y., Miki H., Choraku M., et al. Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol 2007, 86:180-185.